Michael S Levine

List of Publications by Year
in descending order

134	12,447	18482 62	25787 108
papers	citations	h-index	g-index

137	137	137	10152
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Synaptic Dysfunction in Huntingtonâ€™s Disease: Lessons from Genetic Animal Models. Neuroscientist, 2022, 28, 20-40.	3.5	28
2	Synaptic pathology in Huntington's disease: Beyond the corticostriatal pathway. Neurobiology of Disease, 2022, 162, 105574.	4.4	21
3	Adult glut3 homozygous null mice survive to demonstrate neural excitability and altered neurobehavioral responses reminiscent of neurodevelopmental disorders. Experimental Neurology, 2021, 338, 113603.	4.1	1
4	Early impairment of thalamocortical circuit activity and coherence in a mouse model of Huntington's disease. Neurobiology of Disease, 2021, 157, 105447.	4.4	5
5	Calcium dysregulation and compensation in cortical pyramidal neurons of the R6/2 mouse model of Huntingtonâ€™s disease. Journal of Neurophysiology, 2021, 126, 1159-1171.	1.8	5
6	The mouse corticoâ€“basal gangliaâ€“thalamic network. Nature, 2021, 598, 188-194.	27.8	126
7	Cortical Network Dynamics Is Altered in Mouse Models of Huntingtonâ€™s Disease. Cerebral Cortex, 2020, 30, 2372-2388.	2.9	18
8	Neuronal Network Topology Indicates Distinct Recovery Processes after Stroke. Cerebral Cortex, 2020, 30, 6363-6375.	2.9	20
9	Mechanisms underlying the enhancement of Î³â€aminobutyric acid responses in the external globus pallidus of R6/2 Huntingtonâ€™s disease model mice. Journal of Neuroscience Research, 2020, 98, 2349-2356.	2.9	6
10	Paroxysmal Discharges in Tissue Slices From Pediatric Epilepsy Surgery Patients: Critical Role of GABAB Receptors in the Generation of Ictal Activity. Frontiers in Cellular Neuroscience, 2020, 14, 54.	3.7	10
11	Mutant huntingtin reduction in astrocytes slows disease progression in the bachd conditional huntingtonâ€™s disease mouse model. Human Molecular Genetics, 2019, 28, 487-500.	2.9	63
12	Major Contribution of Somatostatin-Expressing Interneurons and Cannabinoid Receptors to Increased GABA Synaptic Activity in the Striatum of Huntingtonâ€™s Disease Mice. Frontiers in Synaptic Neuroscience, 2019, 11, 14.	2.5	28
13	Gain Modulation by Corticostriatal and Thalamostriatal Input Signals during Reward-Conditioned Behavior. Cell Reports, 2019, 29, 2438-2449.e4.	6.4	18
14	Striatal <scp>GABA</scp>ergic interneuron dysfunction in the Q175 mouse model of Huntington's disease. European Journal of Neuroscience, 2019, 49, 79-93.	2.6	27
15	Complete but not partial inhibition of glutamate transporters exacerbates cortical excitability in the R6/2 mouse model of Huntingtonâ€™s disease. CNS Neuroscience and Therapeutics, 2019, 25, 509-518.	3.9	7
16	Therapeutic effects of stem cells in rodent models of Huntington's disease: Review and electrophysiological findings. CNS Neuroscience and Therapeutics, 2018, 24, 329-342.	3.9	17
17	Striatal Direct and Indirect Pathway Output Structures Are Differentially Altered in Mouse Models of Huntington's Disease. Journal of Neuroscience, 2018, 38, 4678-4694.	3.6	28
18	Human Neural Stem Cell Transplantation Rescues Functional Deficits in R6/2 and Q140 Huntington's Disease Mice. Stem Cell Reports, 2018, 10, 58-72.	4.8	76

#	Article	IF	Citations
19	Altered lactate metabolism in Huntington's disease is dependent on <scp>GLUT</scp>3 expression. CNS Neuroscience and Therapeutics, 2018, 24, 343-352.	3.9	22
20	Cellular antiseizure mechanisms of everolimus in pediatric tuberous sclerosis complex, cortical dysplasia, and nonâ€“mTORâ€mediated etiologies. Epilepsia Open, 2018, 3, 180-190.	2.4	13
21	Neural Deletion of Glucose Transporter Isoform 3 Creates Distinct Postnatal and Adult Neurobehavioral Phenotypes. Journal of Neuroscience, 2018, 38, 9579-9599.	3.6	19
22	Neurophysiological Assessment of Huntingtonâ€™s Disease Model Mice. Methods in Molecular Biology, 2018, 1780, 163-177.	0.9	3
23	ENPP1 Enzyme Replacement Prevents the Osteomalacia and Paradoxical Mineralization in the Enpp1 asj/asj mouse model of Autosomal Recessive Hypophosphatemic Rickets Typeâ€2.. FASEB Journal, 2018, 32, 816.13.	0.5	0
24	Parvalbumin Interneurons Modulate Striatal Output and Enhance Performance during Associative Learning. Neuron, 2017, 93, 1451-1463.e4.	8.1	107
25	Differential electrophysiological and morphological alterations of thalamostriatal and corticostriatal projections in the R6/2 mouse model of Huntington's disease. Neurobiology of Disease, 2017, 108, 29-44.	4.4	43
26	Sex-Specific Life Course Changes in the Neuro-Metabolic Phenotype of Glut3 Null Heterozygous Mice: Ketogenic Diet Ameliorates Electroencephalographic Seizures and Improves Sociability. Endocrinology, 2017, 158, 936-949.	2.8	20
27	Epilepsy in Other Neurodegenerative Disorders: Huntingtonâ€™s and Parkinsonâ€™s Diseases. , 2017, , 1043-1058.		4
28	Quantitative Electroencephalographic Biomarkers in Preclinical and Human Studies of Huntingtonâ€™s Disease: Are They Fit-for-Purpose for Treatment Development?. Frontiers in Neurology, 2017, 8, 91.	2.4	18
29	Basolateral Amygdala to Orbitofrontal Cortex Projections Enable Cue-Triggered Reward Expectations. Journal of Neuroscience, 2017, 37, 8374-8384.	3.6	154
30	Rasmussen encephalitis tissue transfer program. Epilepsia, 2016, 57, 1005-1007.	5.1	3
31	Partial Amelioration of Peripheral and Central Symptoms of Huntingtonâ€™s Disease via Modulation of Lipid Metabolism. Journal of Huntington's Disease, 2016, 5, 65-81.	1.9	17
32	Altered membrane properties and firing patterns of external globus pallidus neurons in the R6/2 mouse model of Huntington's disease. Journal of Neuroscience Research, 2016, 94, 1400-1410.	2.9	17
33	In Rasmussen Encephalitis, Hemichannels Associated with Microglial Activation are linked to Cortical Pyramidal Neuron Coupling: A Possible Mechanism for Cellular Hyperexcitability. CNS Neuroscience and Therapeutics, 2015, 21, 152-163.	3.9	30
34	Cholesterolâ€loaded nanoparticles ameliorate synaptic and cognitive function in <scp>H</scp> untington's disease mice. EMBO Molecular Medicine, 2015, 7, 1547-1564.	6.9	84
35	Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease. Journal of Neurophysiology, 2015, 113, 2953-2966.	1.8	73
36	JAKMIP1, a Novel Regulator of Neuronal Translation, Modulates Synaptic Function and Autistic-like Behaviors in Mouse. Neuron, 2015, 88, 1173-1191.	8.1	34

#	Article	IF	Citations
37	Basic Mechanisms of Epileptogenesis in Pediatric Cortical Dysplasia. CNS Neuroscience and Therapeutics, 2015, 21, 92-103.	3.9	78
38	Enhanced GABAergic Inputs Contribute to Functional Alterations of Cholinergic Interneurons in the R6/2 Mouse Model of Huntingtonâ€™s Disease. ENeuro, 2015, 2, ENEURO.0008-14.2015.	1.9	42
39	Forebrain deletion of the dystonia protein torsinA causes dystonic-like movements and loss of striatal cholinergic neurons. ELife, 2015, 4, e08352.	6.0	92
40	Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease. Nature Medicine, 2014, 20, 536-541.	30.7	177
41	Targeted expression of Î¼-opioid receptors in a subset of striatal direct-pathway neurons restores opiate reward. Nature Neuroscience, 2014, 17, 254-261.	14.8	118
42	The role of dopamine in huntington's disease. Progress in Brain Research, 2014, 211, 235-254.	1.4	117
43	Pacemaker GABA synaptic activity may contribute to network synchronization in pediatric cortical dysplasia. Neurobiology of Disease, 2014, 62, 208-217.	4.4	50
44	Differential Synaptic and Extrasynaptic Glutamate-Receptor Alterations in Striatal Medium-Sized Spiny Neurons of Aged YAC128 Huntingtonâ€™s Disease Mice. PLOS Currents, 2014, 6, .	1.4	14
45	A failure in energy metabolism and antioxidant uptake precede symptoms of Huntingtonâ€™s disease in mice. Nature Communications, 2013, 4, 2917.	12.8	96
46	Frontal cortical synaptic communication is abnormal in Disc1 genetic mouse models of schizophrenia. Schizophrenia Research, 2013, 146, 264-272.	2.0	26
47	Multiple Sources of Striatal Inhibition Are Differentially Affected in Huntington's Disease Mouse Models. Journal of Neuroscience, 2013, 33, 7393-7406.	3.6	106
48	Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility. Frontiers in Neuroscience, 2013, 7, 114.	2.8	126
49	White Matter Loss in a Mouse Model of Periventricular Leukomalacia Is Rescued by Trophic Factors. Brain Sciences, 2013, 3, 1461-1482.	2.3	10
50	A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease. Journal of Neurophysiology, 2012, 107, 677-691.	1.8	61
51	Abnormal brain metabolism as a biomarker for evaluating therapeutic approaches in Huntingtonâ€™s disease. Future Neurology, 2012, 7, 527-530.	0.5	8
52	2B or Not 2B: A Tail of Two NMDA Receptor Subunits. Neuron, 2012, 74, 426-428.	8.1	3
53	Functional Differences Between Direct and Indirect Striatal Output Pathways in Huntington's Disease. Journal of Huntington's Disease, 2012, 1, 17-25.	1.9	52
54	Cognitive Deficits in Huntingtonâ€™s Disease: Insights from Animal Models. Current Translational Geriatrics and Experimental Gerontology Reports, 2012, 1, 29-38.	0.7	3

#	Article	IF	Citations
55	Enhanced GABAergic network and receptor function in pediatric cortical dysplasia Type IIB compared with Tuberous Sclerosis Complex. Neurobiology of Disease, 2012, 45, 310-321.	4.4	55
56	Dissecting the contribution of individual receptor subunits to the enhancement of N-methyl-D-aspartate currents by dopamine D1 receptor activation in striatum. Frontiers in Systems Neuroscience, 2011, 5, 28.	2.5	46
57	Altered Balance of Activity in the Striatal Direct and Indirect Pathways in Mouse Models of Huntington's Disease. Frontiers in Systems Neuroscience, 2011, 5, 46.	2.5	70
58	Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human Î±â€šynuclein. Journal of Neuroscience Research, 2011, 89, 1091-1102.	2.9	144
59	Forebrain Striatal-Specific Expression of Mutant Huntingtin Protein in Vivo Induces Cell-Autonomous Age-Dependent Alterations in Sensitivity to Excitotoxicity and Mitochondrial Function. ASN Neuro, 2011, 3, AN20110009.	2.7	25
60	Differential Electrophysiological Changes in Striatal Output Neurons in Huntington's Disease. Journal of Neuroscience, 2011, 31, 1170-1182.	3.6	125
61	Electrophysiological Analysis of Movement Disorders in Mice. Neuromethods, 2011, , 221-239.	0.3	0
62	Alphaâ€šynuclein overexpression in mice alters synaptic communication in the corticostriatal pathway. Journal of Neuroscience Research, 2010, 88, 1764-1776.	2.9	57
63	Genetic Mouse Models of Huntington's Disease: Focus on Electrophysiological Mechanisms. ASN Neuro, 2010, 2, AN20090058.	2.7	80
64	Alterations in Striatal Synaptic Transmission are Consistent across Genetic Mouse Models of Huntington's Disease. ASN Neuro, 2010, 2, AN20100007.	2.7	68
65	Comparative study of cellular and synaptic abnormalities in brain tissue samples from pediatric tuberous sclerosis complex and cortical dysplasia type II. Epilepsia, 2010, 51, 160-165.	5.1	45
66	Dopamine modulation of excitatory currents in the striatum is dictated by the expression of D1 or D2 receptors and modified by endocannabinoids. European Journal of Neuroscience, 2010, 31, 14-28.	2.6	87
67	Location, Location, Location: Contrasting Roles of Synaptic and Extrasynaptic NMDA Receptors in Huntington's Disease. Neuron, 2010, 65, 145-147.	8.1	28
68	Dopamine and Glutamate in Huntington's Disease: A Balancing Act. CNS Neuroscience and Therapeutics, 2010, 16, 163-178.	3.9	143
69	Alterations in Corticostriatal Synaptic Function in Huntington's and Parkinson's Diseases. Handbook of Behavioral Neuroscience, 2010, , 607-623.	0.7	4
70	Epileptogenesis and Cortical Dysplasias. , 2010, , 353-357.		2
71	Rescuing the Corticostriatal Synaptic Disconnection in the R6/2 Mouse Model of Huntingtonâ€™s Disease: Exercise, Adenosine Receptors and Ampakines. PLOS Currents, 2010, 2, RRN1182.	1.4	37
72	Dopamine Receptor Modulation of Glutamatergic Neurotransmission. , 2010, , 281-302.		1

#	Article	IF	Citations
73	Alterations in Cortical Excitation and Inhibition in Genetic Mouse Models of Huntington's Disease. Journal of Neuroscience, 2009, 29, 10371-10386.	3.6	152
74	Differential Susceptibility to Excitotoxic Stress in YAC128 Mouse Models of Huntington Disease between Initiation and Progression of Disease. Journal of Neuroscience, 2009, 29, 2193-2204.	3.6	123
75	Age-Dependent Alterations of Corticostriatal Activity in the YAC128 Mouse Model of Huntington Disease. Journal of Neuroscience, 2009, 29, 2414-2427.	3.6	160
76	Assessment and surgical outcomes for mild type I and severe type II cortical dysplasia: A critical review and the UCLA experience. Epilepsia, 2009, 50, 1310-1335.	5.1	345
77	Neuronal coupling via connexin36 contributes to spontaneous synaptic currents of striatal mediumâ€sized spiny neurons. Journal of Neuroscience Research, 2008, 86, 2147-2158.	2.9	28
78	Pyramidal cell responses to Î³â€aminobutyric acid differ in type I and type II cortical dysplasia. Journal of Neuroscience Research, 2008, 86, 3151-3162.	2.9	24
79	Differential electrophysiological properties of dopamine D1 and D2 receptorâ€containing striatal mediumâ€sized spiny neurons. European Journal of Neuroscience, 2008, 27, 671-682.	2.6	174
80	Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice. Journal of Neuroscience, 2008, 28, 6182-6195.	3.6	558
81	Cytomegalic Interneurons. Journal of Neuropathology and Experimental Neurology, 2007, 66, 491-504.	1.7	73
82	The corticostriatal pathway in Huntington's disease. Progress in Neurobiology, 2007, 81, 253-271.	5.7	287
83	Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Molecular Neurodegeneration, 2007, 2, 8.	10.8	108
84	A Hypothesis Regarding the Pathogenesis and Epileptogenesis of Pediatric Cortical Dysplasia and Hemimegalencephaly Based on MRI Cerebral Volumes and NeuN Cortical Cell Densities. Epilepsia, 2007, 48, 74-78.	5.1	21
85	Immature Neurons and GABA Networks May Contribute to Epileptogenesis in Pediatric Cortical Dysplasia. Epilepsia, 2007, 48, 79-85.	5.1	88
86	Dopamine Reduction of GABA Currents in Striatal Medium-sized Spiny Neurons is Mediated Principally by the D1 Receptor Subtype. Neurochemical Research, 2007, 32, 229-240.	3.3	15
87	Dysfunctional channels are making noise in CAG triplet repeat disorders. Experimental Neurology, 2006, 202, 267-270.	4.1	1
88	Epileptogenesis in pediatric cortical dysplasia: The dysmature cerebral developmental hypothesis. Epilepsy and Behavior, 2006, 9, 219-235.	1.7	184
89	Altered Cortical Glutamate Receptor Function in the R6/2 Model of Huntington's Disease. Journal of Neurophysiology, 2006, 95, 2108-2119.	1.8	69
90	Changes in Expression of N-Methyl-D-Aspartate Receptor Subunits Occur Early in the R6/2 Mouse Model of Huntingtonâ€™s Disease. Developmental Neuroscience, 2006, 28, 230-238.	2.0	37

#	Article	IF	Citations
91	Activation, Proliferation and Commitment of Endogenous Stem/Progenitor Cells to the Oligodendrocyte Lineage by TS1 in a Rat Model of Dysmyelination. Developmental Neuroscience, 2006, 28, 488-498.	2.0	13
92	Contralateral hemimicrencephaly and clinicalâ€“pathological correlations in children with hemimegalencephaly. Brain, 2006, 129, 352-365.	7.6	109
93	Where Do You Think You Are Going? The NMDA-D1 Receptor Trap. Science Signaling, 2006, 2006, pe20.	3.6	113
94	Are Cytomegalic Neurons and Balloon Cells Generators of Epileptic Activity in Pediatric Cortical Dysplasia?. Epilepsia, 2005, 46, 82-88.	5.1	89
95	Functional and molecular development of striatal fastâ€spiking GABAergic interneurons and their cortical inputs. European Journal of Neuroscience, 2005, 22, 1097-1108.	2.6	60
96	Electrophysiological alterations in subthalamic neurons after unilateral dopamine depletion in the rat. Journal of Neuroscience Research, 2005, 80, 203-210.	2.9	13
97	Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease. Journal of Neuroscience Research, 2005, 82, 377-386.	2.9	85
98	Age-Dependent Biphasic Changes in Ischemic Sensitivity in the Striatum of Huntington's Disease R6/2 Transgenic Mice. Journal of Neurophysiology, 2005, 93, 758-765.	1.8	11
99	Striatal Potassium Channel Dysfunction in Huntington's Disease Transgenic Mice. Journal of Neurophysiology, 2005, 93, 2565-2574.	1.8	98
100	Dopamine and Glutamate in Huntingtonâ€™s Disease. , 2005, , 539-565.		3
101	Synaptic Alterations in Genetic Mouse Models of Huntingtonâ€™s and Parkinsonâ€™s Diseases: Is there a Common Thread?. , 2005, , 361-370.		0
102	Modulation of AMPA currents by D2 dopamine receptors in striatal medium-sized spiny neurons: are dendrites necessary?. European Journal of Neuroscience, 2004, 19, 2455-2463.	2.6	71
103	Increased GABAergic function in mouse models of Huntington's disease: Reversal by BDNF. Journal of Neuroscience Research, 2004, 78, 855-867.	2.9	117
104	Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human Â-Synuclein. Journal of Neuroscience, 2004, 24, 9434-9440.	3.6	428
105	Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends in Neurosciences, 2004, 27, 691-697.	8.6	170
106	Heterosynaptic Dopamine Neurotransmission Selects Sets of Corticostriatal Terminals. Neuron, 2004, 42, 653-663.	8.1	337
107	Morphological and electrophysiological characterization of abnormal cell types in pediatric cortical dysplasia. Journal of Neuroscience Research, 2003, 72, 472-486.	2.9	179
108	Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons. Journal of Biological Chemistry, 2003, 278, 43628-43635.	3.4	784

#	Article	IF	Citations
109	Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease. Journal of Neuroscience, 2003, 23, 961-969.	3.6	327
110	Dopamine Enhancement of NMDA Currents in Dissociated Medium-Sized Striatal Neurons: Role of D1 Receptors and DARPP-32. Journal of Neurophysiology, 2002, 88, 3010-3020.	1.8	244
111	Striatal neurochemical changes in transgenic models of Huntington's disease. Journal of Neuroscience Research, 2002, 68, 716-729.	2.9	88
112	Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease. Journal of Neuroscience, 2001, 21, 9112-9123.	3.6	266
113	Electrophysiological and Morphological Changes in Striatal Spiny Neurons in R6/2 Huntington's Disease Transgenic Mice. Journal of Neurophysiology, 2001, 86, 2667-2677.	1.8	295
114	Differential sensitivity of mediumâ€•and largeâ€sized striatal neurons to NMDA but not kainate receptor activation in the rat. European Journal of Neuroscience, 2001, 14, 1577-1589.	2.6	35
115	NMDA receptor function in mouse models of Huntington disease. Journal of Neuroscience Research, 2001, 66, 525-539.	2.9	246
116	Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nature Genetics, 2000, 26, 300-306.	21.4	495
117	Neurons Recorded from Pediatric Epilepsy Surgery Patients with Cortical Dysplasia. Epilepsia, 2000, 41, S162-S167.	5.1	66
118	Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. Journal of Neuroscience Research, 1999, 58, 515-532.	2.9	316
119	Enhanced sensitivity to Nâ€methylâ€Dâ€aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. Journal of Neuroscience Research, 1999, 58, 515-532.	2.9	10
120	Dopaminergic modulation of early signs of excitotoxicity in visualized rat neostriatal neurons. European Journal of Neuroscience, 1998, 10, 3491-3497.	2.6	46
121	Dopamine and N-Methyl-D- Aspartate Receptor Interactions in the Neostriatum. Developmental Neuroscience, 1998, 20, 1-18.	2.0	360
122	Striatal Excitatory Amino Acid Receptor Subunit Expression in the D_{1A}-Dopamine Receptor-Deficient Mouse. Developmental Neuroscience, 1998, 20, 237-241.	2.0	12
123	Postnatal Development of Glutamate Receptor-Mediated Responses in the Neostriatum. Developmental Neuroscience, 1998, 20, 154-163.	2.0	70
124	Dopaminergic Modulation of NMDA-Induced Whole Cell Currents in Neostriatal Neurons in Slices: Contribution of Calcium Conductances. Journal of Neurophysiology, 1998, 79, 82-94.	1.8	278
125	Agonist-induced morphologic decrease in cellular d1A dopamine receptor staining. Synapse, 1997, 27, 313-321.	1.2	29
126	Modulatory Actions of Dopamine on NMDA Receptor-Mediated Responses Are Reduced in D1A-Deficient Mutant Mice. Journal of Neuroscience, 1996, 16, 5870-5882.	3.6	158

#	Article	IF	Citations
127	Glutamate receptor-induced toxicity in neostriatal cells. Brain Research, 1996, 724, 205-212.	2.2	32
128	Neuromodulatory actions of dopamine on synaptically-evoked neostriatal responses in slices. Synapse, 1996, 24, 65-78.	1.2	150
129	Dye-Coupling in Human Neocortical Tissue Resected from Children with Intractable Epilepsy. Cerebral Cortex, 1993, 3, 95-107.	2.9	29
130	Differential modulation by dopamine of responses evoked by excitatory amino acids in human cortex. Synapse, 1992, 11, 330-341.	1.2	161
131	Iontophoretic application of NMDA produces different types of excitatory responses in developing human cortical and caudate neurons. Neuroscience Letters, 1991, 126, 167-171.	2.1	24
132	Dye-Coupling in the neostriatum of the rat: I. Modulation by dopamine-depleting lesions. Synapse, 1989, 4, 229-237.	1.2	120
133	Dye-Coupling in the neostriatum of the rat: II. Decreased coupling between neurons during development. Synapse, 1989, 4, 238-247.	1.2	62
134	Postnatal development of caudate input neurons in the cat. Journal of Comparative Neurology, 1983, 219, 51-69.	1.6	37